L-Arginine and Sickle Cell Disease
A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 90035-001
- Hospital de Clinicas de Porto Alegre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of sickle cell disease confirmed through hemoglobin electrophoresis
- Genotypes SS, SC and Sβ thalassemia
- Age > 1 year
Exclusion Criteria:
- Liver dysfunction (alanine aminotransferase ALT > 3 times the normal levels
- Renal dysfunction (creatinine > twice the normal levels)
- Increase in methemoglobin levels (> 5 times the normal levels)
- History of recent stroke (< 1 month) and priapism
- Pregnancy
- Allergy to L-arginine
- Use of sildenafil, calcium channel blockers, nitroglycerin or other nitrates
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: L-arginine
0.1g/kg/day for 6 months
|
L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
Mannitol was administered orally at a dose of 01 g/kg/day for six months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tricuspid regurgitant jet velocity >2.5 m/s
Time Frame: 6 months
|
Tricuspid regurgitant jet velocity was used to assess pulmonary arterial hypertension before and after treatment with L-arginine.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lactate dehydrogenase levels
Time Frame: 6 months
|
The effect of L-argigine administration on hemolysis was assessed through the variation of serum levels of lactate dehydrogenase.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 04-487 cep@hcpa.ufrgs.br
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.